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Abstract
Background: Fabry disease (FD), an X-linked lysosomal storage disorder, is caused by a reduced activity of the
lysosomal enzyme a-galactosidase A. The disorder ultimately leads to organ damage (including renal failure) in
males and females. However, heterozygous females usually present a milder phenotype with a later onset and a
slower progression.
Methods: A combined enzymatic and genetic strategy was used, measuring the activity of a-galactosidase A and
genotyping the a-galactosidase A gene (GLA) in dried blood samples (DBS) of 911 patients undergoing
haemodialysis in centers across Spain.
Results: GLA alterations were found in seven unrelated patients (4 males and 3 females). Two novel mutations (p.
Gly346AlafsX347 and p.Val199GlyfsX203) were identified as well as a previously described mutation, R118C. The
R118C mutation was present in 60% of unrelated patients with GLA causal mutations. The D313Y alteration,
considered by some authors as a pseudo-deficiency allele, was also found in two out of seven patients.
Conclusions: Excluding the controversial D313Y alteration, FD presents a frequency of one in 182 individuals
(0.55%) within this population of males and females undergoing haemodialysis. Moreover, our findings suggest
that a number of patients with unexplained and atypical symptoms of renal disease may have FD. Screening
programmes for FD in populations of individuals presenting severe kidney dysfunction, cardiac alterations or
cerebrovascular disease may lead to the diagnosis of FD in those patients, the study of their families and
eventually the implementation of a specific therapy.
Background
Fabry disease (MIM 301500) is an X-linked lysosomal
storage disorder resulting from mutations in the a-
galactosidase A gene (GLA), leading to a reduction in
the activity of the lysosomal enzyme a-galactosidase A
(a-Gal A) [1]. This enzyme defect generates progressive
accumulation of globotriaosylceramide (Gb3) and related
glycosphingolipids, primarily in the vascular endothe-
lium leading to renal failure, cardiac and cerebrovascular
disease [1,2].
In general, males with a deficient activity of a-Gal A
exhibit the classical FD phenotype with angiokeratomas,
acroparesthesias, hypohidrosis, and corneal and
lenticular opacities, with onset occurring in childhood.
Heterozygous females usually present a milder pheno-
type, showing a slower progression. However the clinical
manifestations of FD in females are highly heteroge-
neous due to the random X-chromosome inactivation
[3]. Therefore, some heterozygous females develop
severe manifestations of FD including renal disorder [4].
Clinical variants of FD in male patients with residual
activity of a-Gal A have been described. These patients
show milder phenotypes and a later onset than those
presenting classical symptoms of the disease. Patients
with the cardiac variant of FD usually develop clinical
symptoms in the sixth decade. These patients present
left ventricular hypertrophy (LVH) and/or cardiomyopa-
thy [5-8], and may also develop some degree of protei-
nuria and renal insufficiency [9]. Patients with the ‘renal
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stage, which can eventually progress to end-stage renal
failure, being one of the major causes of morbidity and
mortality among patients with classic FD [9]. The preva-
lence of FD has been estimated to have a range between
one in 117 000 births and one in 40 000 males [1,10,11],
but the precise prevalence is unknown. An accurate esti-
mation of its epidemiology is difficult to do because FD
is clinically very heterogeneous and its early classic man-
ifestations tend to be non-specific and often unrecog-
nized. Patients are therefore frequently misdiagnosed, or
not diagnosed until late in life [1,12]. Recently a new-
born screening showed an incidence of one in 3100 live-
newborns, accordingly with this study the later-onset
forms of FD present a surprisingly high incidence [13].
This finding is confirmed by recent screening studies of
patients undergoing haemodialysis which indicated that
the number of patients with unrecognized FD is much
greater than the one reported in the dialysis registry
data from the USA and Europe [14-16]. Diagnosis of FD
(e.g. through screening) is important since it allows the
treatment with a specific therapy of affected patients as
well as the identification of asymptomatic affected rela-
tives and genetic counselling for couples at risk.
The frequency of FD in Spanish patients undergoing
haemodialysis has not been reported to date. The aim of
this study was to identify FD patients within male and
female patients undergoing haemodialysis. Reduced a-
Gal A activity was used as a biochemical marker of FD
and to select patients for further studies by genotype
analysis. In this study, we report for the first time the
frequency of FD in a Spanish population of individuals
in haemodialysis.
Results
Patients
All the patients (males and females) undergoing haemo-
dialysis and that signed the informed consent were
included in the screening. Data were available for 911
individuals (543 males and 368 females). The two
groups did not differ significantly in age, being the
m e a na g eo f6 6 . 2( r a n g e2 0 . 7-9 1 . 1 )a n d6 6 . 9( 2 0 . 2-
90.4) for males and female patients, respectively.
a-Gal A activity and genotype analysis
The mean value for a-Gal A activity in the 911 DBS
samples was 0.625 ± 0.326 nmol/h/spot, similar to the
mean value of 0.620 nmol/h/spot of the reference
values. Thirty individuals (5.5%), out of the 543 males
presented levels of a-Gal A activity below the minimum
control range, which corresponded to 48% of the control
mean (0.3 nmol/h/spot; Figure 1). One hundred and
twenty five females (34%) out of 368 females screened
present enzymatic activities below the previously defined
cut-off, which corresponded to 80% of the control mean
(0.5 nmol/h/spot; Figure 1). In this study, it can not be
completely excluded that some heterozygous could
remain unidentified since genotyping is the most reliable
method to identify FD among females. The used cut-off
was selected on the basis of previous experience in diag-
nosis of female Fabry patients, which usually present
activities lower than 60% the control mean. The lowest
values obtained for a-Gal A activity was 0.001 nmol/h/
spot in male patients, and 0.15 nmol/h/spot in female
patients.
Denaturing high-performance liquid chromatography
(DHPLC) analysis was performed in the 155 samples
from male and female individuals showing a-Gal A
activity below the pre-defined minimum. DNA altera-
tions were found in 48 of these samples, from which 40
were polymorphisms or sequence variants (data not
shown). Gene amplification and sequencing of single-
stranded genomic DNA from the remaining eight sam-
ples led to the identification of two novel mutations (p.
Gly346AlafsX347 and p.Val199GlyfsX203), and two pre-
viously described alterations, the R118C mutation and
the D313Y alteration [13,17-21]. (Table1 and Figure 2).
The a-Gal A enzymatic activity in the eight patients
with FD identified ranged between 0.001 and 0.292
nmol/h/spot in males and from 0.153 to 0.770 nmol/h/
spot in females. Whenever the leukocytes from the iden-
tified FD patients were available, the a-gal A activity
was determined in these cells and the results obtained
confirmed the values obtained in DBS. (Table 1)
The two novel mutations identified, in patient #7
(Table 1), a guanine deletion produced a premature stop
codon instead of transcription and translation to leucine.
In patient #6, p.Val199GlyfsX203 in exon 4 also caused
af r a m e s h i f ta n dt h ea p p e a r a n c eo fap r e m a t u r es t o p
codon at amino acid position 203 instead of a glutamic
Figure 1 a-galactosidase A activity in control samples and in a
haemodialysis population with both genders.
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Page 2 of 7Table 1 Characteristics of patients identified in the screening
Patient Characteristics Mutation Sex Age,
years
a-Gal A
activity on
Leukocytes,
nmol/h/mg of
protein
a-Gal A
activity
on DBS,
nmol/h/
spot
a-Gal A mutation
Genomic
Reference
Sequence
(X14448)
Coding
DNA
Reference
Sequence
(X14448)
1 Angiokeratoma; fever episodes;
hypohidrosis; gastrointestinal
problems; proteinuria; progressive
hearing loss; valvular dysfunction and
arrhythmias; stroke at 71 years; Mother
died due to a Transient Ischemic
Attack (TIA).
R118C Male 72 20 (35% of
control mean)
0.164 (26%
of control
mean)
g.5251 C>T c.352 C>T
2 Abdominal pain; nephropathy; left
nephrectomy; cataracts; progressive
loss of vision. Sister diagnosed with
FD. Presents Front temporal sub
cortical and cortical atrophy;
periventricular hypodensity of white
matter
R118C Male 83 n.a. 0.122 (20%
of control
mean)
g.5251 C>T c.352 C>T
3 End-Stage Renal Disease (ESRD), LHV,
valvular dysfunction
D313Y Female 80 28 (49% of
control mean)
0.371 (59%
of control
mean)
g.10645 G>T c.937 C>T
4* Proteinuria glomerulosclerosis and
hyalosis in kidney biopsy; kidney
transplantation failure; HBP; Human
Immunodeficiency Virus (HIV); An
uncle and a cousin with kidney
dysfunction. Another cousin with
hypoacusia
R118C Female 47 45 (79% of
control mean)
0.592 (94%
of control
mean)
g.5251 C>T c.352 C>T
5* Sister of patient 4 also identified as an
index patient. LVH in dilatation phase
and multi-valvular disease; HBP.
Pigmentary macular edema; Cirrhosis,
HIV; Son and sister with FD; Both with
proteinuria.
R118C Female 50 34 (60% of
control mean)
0.770
(123% of
control
mean)
g.5251 C>T c.352 C>T
6 Angiokeratoma; acroparesthesia; fever
episodes; abdominal pain;
nephropathy; policysts; LVH, auricular
fibrillation; acute myocardial infarction.
Two daughters diagnosed with FD
p.Val199GlyfsX203 Female 58 n.a 0.153 (24%
of control
mean)
g.8368_8369
insG
c.595_596
ins G
7 Nephropathy; Psychological problems;
kidney transplant, TIA, valvular
dysfunction, arrhythmias patient
refused to be studied. Relative
diagnosed with FD
p.Gly346AlafsX347 Male 54 n.a. 0.001 (0%
of control
mean)
g.11016delG c.1037 delG
8 Dyspnea, palpitations, proteinuria,
kidney transplant, LHV, valvular
dysfunction, arrhythmias.
D313Y Male 74 22 (39% of
control mean)
0.292 (46%
of control
mean)
g.10645 G>T c.937 C>T
Control Values DBS - Mean -> 0.62 nmol\h\spot; Minimum -> 0.3 nmol\h\spot
Leucocytes - Mean -> 57 nmol\h\mg of protein; Minimum -> 28 nmol\h\mg of protein
() - Percentage of the mean value obtained in controls and patients, respectively;
n.a. - not available; * - sisters
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Page 3 of 7acid. The two novel mutations were undetected in 180
X-chromosomes from unaffected individuals (60 males
and 60 females control samples), which indicated that
they were not common sequence variants or poly-
morphisms. The two novel mutations lead to a stop
codon, and therefore to the truncation of the resulting
protein product. As expected, like in other truncated
proteins, no functional enzyme was found, as observed
by the lack of enzyme activity (data not shown). Patients
3 and 8 presented the D313Y alteration, the so called
‘pseudo-deficiency allele’ [19,22]. The previously
described GLA R118C mutation [13,21] was found in
four patients (#1, #2, #4 and #5) (Table 1) following
DHPLC and sequencing analysis. Although patients #4
and #5 were identified independently, they were found
to be sisters. The residual a-Gal A activity range
between 0.122-0.164 nmo1/h/hspot in hemizygous FD
patients with the R118C mutation. This C-T substitu-
tion in codon 118, results in the replacement of the
strongly basic amino acid arginine by the neutral, poten-
tially sulphydryl-binding, cysteine. The residual a-Gal A
activity in hemizygous individuals presenting the R118C
or the D313Y was 22% and 40% of the control mean,
respectively. These results were confirmed in leukocytes
and plasma of patient #1 (R118C) which showed an
enzymatic activity corresponding to 35% and 67% of the
control mean in leukocytes and plasma, respectively,
and of patient #8 ( D313Y) which presented an activity
corresponding to 39% and 29% of control mean, respec-
tively (see Table1).
In order to ascertain if the haemodialysis patients with
FD mutations were from a particular region of Spain,
they were classified according to their geographical area
(Figure 3). This showed a random, non-clustered distri-
bution of several mutations. Distribution of the two fre-
quent alterations, R118C and D313Y, was spread across
Spain, suggesting that their high frequency was not due
to founder effects. Moreover the R118C was not found
in 240 alleles from healthy controls, ruling out the pos-
sibility of being a polymorphism.
Discussion
The classic clinical spectrum of FD has been extended
to include a large diversity of symptoms. Patients have
been described with symptoms restricted to the heart
and/or kidney, the so-called renal and cardiac variants
[1,2,5-8]. The renal variant of FD was first described by
Nakao et al. [14] following the screening of patients
undergoing dialysis in Kyushu Island, Japan. The fre-
quency of the renal variant in that study was one in 87
(1.2%) males. In this study, we found seven unrelated
individuals with GLA alterations, five with FD causal
mutations (three male and two females) and two pre-
senting the “pseudo-allele” D313Y [19,22] among the
911 patients undergoing haemodialysis. An overall pre-
valence of one in 182 (0.55%) was estimated, excluding
the two individuals with the D313Y allele, one in 181
among males (0.55%) and one in 184 among females
(0.54%). Although the overall prevalence in our study is
slightly lower than the frequency of the renal variant of
FD found in the Japanese study (1.2%) [14], is signifi-
cantly higher than the prevalence reported by Linthorts
Figure 2 Activity of a-galactosidase A in patients with FD with
different GLA mutations.
Figure 3 Location of participating centres and of patients with
mutations that cause FD.
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screening studies carried out in haemodialysis indivi-
duals. According to this overview a mean prevalence of
0.33% was found in the study of a total of 7182 males
screened in 12 independent studies and a prevalence of
0 . 1 0 %i nt h es c r e e n i n go fat o t a lo f4 1 7 9f e m a l e si n6
studies. In our study we found a similar prevalence of
FD in males (0.55%) and females (0.54%), being the
obtained values 1,6 and 5,4 times higher for males and
females, respectively than the prevalence reported in lit-
erature [23]. These findings suggest that the combined
biochemical and genetic strategy used in our screening
is more efficient in the identification of FD patients, par-
ticularly in the case of heterozygous [23].
All except two of the patients with FD identified in
this study had missense mutations, resulting in residual
activity of a-Gal A. This activity explains why these
patients did not show the early classic manifestations of
FD. Two of the mutations identified had not been
reported previously. The D313Y alteration lead to
reduced activity of a-Gal A and has been associated
with FD presenting with cardiovascular symptoms [20].
In contrast to previously described, where association
between D313Y and other GLA mutations was reported
[24,22], in our study the D313Y was the only GLA
alteration present in the mutated allele. The R118C
mutation is also associated with an amino acid substitu-
tion and residual activity of a-Gal A. Molecular model-
ing of this mutation indicated that the substituted
residue could be accommodated in the crystal structure
of a-Gal A, and that the number of main- and side-
chain atoms that were influenced by this substitution
was similar to other mutations known to produce later-
onset forms of FD [13]. As this mutation appears to
produce a functional enzyme, the reduction in its activ-
ity may result from instability or mis-targeting of the
enzyme.
Our results demonstrate the existence of a frequent
GLA mutation, the R118C in unrelated patients with
FD. In this study the R118C mutation represents 60% of
total unrelated patients and the D313Y represents 20%
of total unrelated patients. A similar R118C frequency
(43%) and D313Y (30%) was observed in a preliminary
screening study of FD in a cardiology risk of Spanish
and Portuguese population (Gaspar and Sá Miranda
unpublished data). Since the R118C mutated enzyme is
characterized by a high residual a-Gal A activity, geno-
type analysis should be carried out in males whose
mean a-Gal A activity is 20-50% of the control mean.
We recommend that biochemical and genotypic assays
should be used as complementary tests to identify
patients with FD.
Description of the pedigrees of the patients with these
mutations is underway for the seven families (two
patients were related). Genetic counselling has been pro-
vided and, after pedigree analysis, diagnostic testing will
be offered to family members who may be affected. The
study of family members has been initiated allowing the
identification of seven FD patients within four families.
The results of this study indicate that the frequency of
FD in patients with renal disease may be underestimated
so far. We therefore propose that FD should be consid-
ered a cause of unexplained features such as cardiome-
galy, arrhythmia and hypohidrosis in patients with renal
disease. Even if patients are receiving maintenance dialy-
sis, anticipating and treating other manifestations of FD
(e.g. cardiac involvement and cerebrovasculopathy) is
important. Moreover, the identification of an index case
allows the study of family members and eventually ways
to the diagnose of presymptomatic FD patients. General
physicians and cardiologists should consider the diagno-
sis of FD in patients with LVH, cardiomyopathy, and
conduction abnormalities, including short PR intervals
and inverted ST segments without evidence of infarc-
tion. Microalbuminuria, or frank proteinuria, isosthe-
nuria, and/or decreasing renal function should alert
physicians to consider FD in the differential diagnosis.
Conclusions
In conclusion, using a combined biochemical and DNA
analysis strategy, we identified seven unrelated patients
with GLA alterations, five with causal mutations (three
males and two females) and two presenting the pseudo-
allele D313Y who were undergoing haemodialysis for
end-stage renal disease without a diagnosis. According
to our results R118C seems to be a frequent GLA muta-
tion in FD representing 60% of total identified mutated
alleles. The two frequent GLA alterations (R118C and
the D313Y) identified are associated with a high residual
a-Gal A activity, suggesting that hemizygous patients
with FD cannot be identified only by enzymatic assay.
Studies to further characterize these GLA alterations are
ongoing to ascertain whether the mutated proteins are
unstable or mis-targeted. Moreover, our results indicate
that there may be a significant number of patients with
end-stage renal disease who have undiagnosed FD. FD
may therefore be more common in patients with renal
disease than previously believed. Studies in other popu-
lations of patients showing possible manifestations of
FD are needed to assess the frequency of the later-onset
phenotypes, particularly because disease frequency may
vary in different ethnic or demographic groups.
Methods
Patients
The whole project was submitted for approval to the
Ethics Committee (IRB) of the Hospital Universitari de
Girona Dr Trueta. The IRB evaluated the project and
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Patients, males and females, undergoing dialysis with
end-stage renal failure of uncertain aetiology were
recruited at eight hospitals (including 17 haemodialysis
centres) from several regions of Spain (Figure 3). Male
and female patients aged over 18 years undergoing dia-
lysis were screened for FD. Patients provided written
informed consent to participate in the study, which
complied with the terms of the Declaration of Helsinki.
The healthy subjects who underwent genetic screening
were volunteers and gave formal informed consent for
the DNA analysis.
Assay for enzyme activity of a-Gal A
Screening for FD was carried out by measuring the activity
of a-Gal A in DBS. Blood samples collected on Whatman
number 903 paper (Whatman, Middlesex, United King-
dom) were kept at room temperature during shipment
and stored at 4°C in zip-lock plastic bags. The name, sex,
date of birth, hospital, physician and date of collection was
recorded on the cards. DBS (diameter, 5 mm) were
obtained from the sample card using a standard paper
punch. DBS samples were added to 96-well micro titre
plates and incubated overnight at 37°C with 4-methylum-
belliferyl-a-D-galactopyranoside (Glycosynth, Warrington,
UK) as a substrate, and N-acetyl-D-galactosamine (Sigma-
Aldrich Quimica, S.A., Sintra, Portugal) as an inhibitor for
a-N-acetylgalactosaminidase. Each plate contained an
internal standard for quality-control purposes. The reac-
tion was stopped with 250 μl Glycine-NaOH(pH 10.5).
The concentration of hydrolysed 4-methylumbelliferyl (4-
MU) was determined by measuring the fluorescence of the
final mixture (excitation 365 nm; emission 450 nm) using
a Cary Eclipse fluorescence spectrophotometer (Varian
Incorporated, Walnut Creek, USA) and by comparison
with 4-MU standards. Enzyme activities were expressed as
nmol/h/spot.
Molecular study
To identify patients with FD who exhibited a-Gal A resi-
dual activity, genotype analysis was carried out in all sam-
ples with enzyme activity lower than 80% or 40% of the
control means in female and male patients, respectively.
The upper limit in the case of the females was chosen
accordingly to the enzymatic activity present in several
heterozygous Fabry patients previously identified by us
and used to validate this strategy. It is important to clar-
ify that the identification of heterozygous for FD must
always be based on genotype analysis. So, in this study,
due to logistic reasons we can not rule out that some het-
erozygous could remain unidentified. DHPLC analysis of
polymerase chain reaction (PCR) products was per-
formed, as previously described [25], in order to identify
genotypic alterations. In the case of exons that showed
variations in their DHPLC profiles, the introns-exons
boundaries were amplified by PCR [25]. The resulting
products were purified using QIAquick PCR Purification
kit (Qiagen, Izasa, Portugal) and the samples were sent to
MWG Biotech (Fraunhoferst, Germany) for sequencing.
Samples from 120 healthy individuals without FD were
used as controls. RFLP (restriction fragment length poly-
morphism) analysis for the frequent mutation R118C was
performed using HinfI (Fermentas, Ontario, Canada)
with a final concentration of 1 U/μl and a final volume of
12 μl for 150 min at 37°C. A mutation was considered to
cause disease if there was co-segregation of the mutation
and the disease phenotype, or if there was low a-Gal A
activity in the affected family.
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